CEL-SCI's patented inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
The LEAPS platform technology, currently being developed as a therapeutic vaccine for rheumatoid arthritis under a USD 1.5m grant from the US National Institutes of Health, is a T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens.
LEAPS compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This platform technology has been shown in several animal models to preferentially direct the immune response to a cellular, humoral, or mixed pathway and has been shown to involve upregulation of T-regulatory cells in some animal models.
It has the potential to be utilised in diseases for which antigenic epitope sequences have already been identified, such as: a number of infectious diseases, some cancers, autoimmune diseases, allergic asthma and allergy, and select central nervous system diseases.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer